Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

MIRTAZAPINE vs MIRVETUXIMAB SORAVTANSINE-GYNX: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

MIRTAZAPINE vs MIRVETUXIMAB SORAVTANSINE-GYNX: Safety Overview

Metric MIRTAZAPINE MIRVETUXIMAB SORAVTANSINE-GYNX
Total FAERS Reports 28,691 1,086
Deaths Reported 5,410 91
Death Rate 18.9% 8.4%
Hospitalizations 11,495 120
Average Patient Age 54.1 yrs 64.3 yrs
% Female Patients 59.6% 99.7%
FDA Approval Date Apr 22, 2004 N/A
Manufacturer REMEDYREPACK INC. N/A
Route ORAL N/A
Marketing Status Prescription Prescription